SQI Diagnostics Adds Autoimmune Disease Expert to Lead its Scientific
Advisory Board
Shoenfeld is currently Head, Department of Medicine 'B' and Center for Autoimmune Diseases, Sheba Medical Center, and Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases,
"We look forward to working with
In November, 2009, the U.S. Food and Drug Administration cleared SQI's automated SQiDworks(TM) Diagnostics Platform and its multiplexed IgXPLEX(TM) rheumatoid arthritis (RA) assay for marketing in the
SQI's IgXPLEX(TM) product pipeline for 2010 includes the highest-demand autoimmune test panels for Celiac Disease, Vasculitis, Lupus and Irritable Bowel Disease (Crohn's disease, ulcerative colitis).
About SQI Diagnostics
SQI Diagnostics is a medical systems company that develops proprietary technology in multiplexing, miniaturization and automation. SQI provides laboratories the ability to simultaneously analyze multiple biomarkers, deliver accurate patient results in less time, significantly reduce labour, and increase profits...All in One Drop. For more information please visit www.sqidiagnostics.com.
Certain information in this press release is based on beliefs and assumptions of the Company's senior management and information currently available to it that may constitute forward-looking information within the meaning of securities laws. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements.
This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
%SEDAR: 00021000E
For further information: Chief Financial Officer, Andrew Morris, (416) 674-9500 ext. 229, [email protected]; Media and Investor Relations, Adam Peeler, (416) 815-0700 ext. 225, [email protected]
Share this article